Targeting the MET oncogene in cancer and metastases

Expert Opinion on Investigational Drugs

Volumn 19, Issue 11, 2010, Pages 1381-1394

  Stella, Giulia M ^a,b   Benvenuti, Silvia ^a   Comoglio, Paolo M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

gene amplification; ligand antagonists; neutralizing antibodies; oncogene addiction; small molecule inhibitors; somatic mutation

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AMG 102; AMG 208; ANTINEOPLASTIC AGENT; ARQ 197; BMS 777607; DN 30; E 7050; EMD 1214063; ERLOTINIB; INCB 28060; JNJ 38877605; L2G7; MGCD 265; MK 2461; MP 470; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; OA 5D5 MONOCLONAL ANTIBODY; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SCH 900195; SGH 523; SGX 523; UNCLASSIFIED DRUG; XL 184; XL 880;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLOOD CLOTTING; BRAIN CANCER; CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; FATIGUE; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; METASTASIS; MOLECULAR MECHANICS; ONCOGENE; PHENOTYPE; PROTEIN PROTEIN INTERACTION; REVIEW; SIDE EFFECT; STOMACH CANCER;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASMS; ONCOGENES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 77958483335     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.522988     Document Type: Review

References (99)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
2. Trusolino L, Comoglio PM. Scatter-factors and semaphoring receptors: cell signaling for invasive growth. Nat Rev Cancer 2002;4:289-300
3. Cross M, Dexter TM. Growth factors in development, transformation and tumorigenesis. Cell 1991;64:271-80
4. Bottaro DP, Rbin JS, Falletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4
5. Naldini L, Weidner KM, Vigna E, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991;10:2867-78
6. Naldini L, Vigna E, Ferracini R, et al. The tyrosine kinase encoded by MET proto oncogene is activated by autophosphorylation. Mol Cell Biol 1991;11:1793-803
7. Traverse S, Gomez N, Paterson H, et al. Sustained activation of mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of effects of nerve growth factor and epidermal growth factor. Biochem J 1992;288:351-5
8. Boccaccio C, Ando M, Comoglio PM. A differentiation switch for genetically modified hepatocytes. FASEB J 2002;16:120-2
9. Comoglio PM, Trusolino L. Invasive growth: from development to metastasis. Clin Invest 2002;109:857-62
10. Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med 2005;11:284-92
11. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met proto-oncogene. Cancer Cell 2003;3:347-61
12. Wojcik EJ, Sharifpoor S, Miller NA, et al. A novel activating function of c-src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene 2006;25:2773-84
13. Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995;1:147-54
14. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006;103:2316-21
15. Lutterbach B, Zeng Q, Davis LJ, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007;67:2081-8
16. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43
17. Houldsworth J, Cordon-Cardo C, Ladanyi C, et al. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 1990;50:6417-22
18. Kuniyasu H, Yasui W, Kitadai Y, et al. Frequent amplification of c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992;189:227-32
19. Hara T, Ooi A, Kobayashi M, et al. Amplification of c-myc, K-sam and c-met gene in gastric cancer: detection fluorescence in situ hybridization. Lab Invest 1998;78:1134-53
20. Miller CT, Lin L, Casper AM, et al. Genomic amplification of MET with boundaries within fragile site FRAG7 and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006;25:409-18
21. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-7
22. Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17:77-88
23. Tong CY, Hui AB, Yin XL, et al. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J Neurosurg 2004;100:187-93
24. COSMIC-Catalogue of Somatic Mutations in Cancer website. Hinxton, Cambridge, UK: Wellcome Trust Sanger Institute, 2010. Available from: http://www.sanger.ac uk/genetics/CGP/cosmic/[Last accessed 15 September 2010]
25. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73
26. Park WS, Dong SM, Kim SY, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999;59:307-10
27. Lee JH, Han SU, Cho H, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000;19:4947-53
28. Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer 2009;63:169-79
29. Puri N, Ahamed S, Janamanchi V, et al. c-MET is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 2007;13:2246-53
30. Lorenzato A, Olivero M, Patane S, et al. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res 2002;62:7025-30
31. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997;57:5391-8
32. Tuck AB, Park M, Sterns E, et al. Co-expression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 1996;148:225-32
33. Ferracini R, Olivero M, Di Renzo MF, et al. Retrogenic expression of the mET proto-oncogene correlates with the invasive phenotype of human rabdomyosarcomas. Oncogene 1996;12:1697-705
34. Ferracini R, Di Renzo MF, Scotlandi K, et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 1995;10:739-49
35. Michieli P, Basilico C, Pennacchietti S, et al. Mutant Met-mediated transformation is ligand-dependent and can be inibite by HGF antagonists. Oncogene 1999;18:5221-31
36. Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-41
37. Trousseau A. Phlegmasia alba dolens. Clinique Médicale de l'Hotel-Dieu de Paris. Volume 3. J. B. Balliere et Fils, Paris; 1865. p. 654-712
38. Boccaccio C, Sabatino G, Medico E, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005;434:396-400
39. Boccaccio C, Comoglio PM. Genetic link between cancer and thrombosis. J Clin Oncol 2009;27:4827-33
40. Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008;18:87-96
41. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16
42. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997;57:5391-8
43. Tuck AB, Park M, Sterns E, et al. Co-expression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 1996;148:225-32
44. Lokker NA, Mark MR, Luis EA, et al. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J 1992;11:2503-10
45. Lietha D, Chirgadze DY, Mulloy B, et al. Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. EMBO J 2001;20:5543-55
46. Lyon M, Deakin JA, Mizuno K, et al. Interaction of hepatocyte growth factor with heparin-sulphate. Elucidation of the major heparin sulphate structural determinants. J Biol Chem 1994;269:11216-23
47. Basilico C, Arnesano A, Galluzzo M, et al. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem 2008;283:21267-77
48. Trusolino L, Pugliese L, Comoglio PM. Interactions between scatter factors and their receptors: hints for therapeutic applications. FASEB J 1998;12:1267-80
49. Montesano R, Soriano JV, Malinda KM, et al. Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis. Cell Growth Differ 1998;9:355-65
50. Tolbert WD, Daugherty-Holtrop J, Gherardi E, et al. Structural basis for agonism and antagonism of hepatocyte growth factor. Proc Natl Acad Sci USA 2010;107:13264-9
51. Matsumoto K, Nakamura T, Sakai K, Nakamura T. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4. Proteomics 2008;8:3360-70
52. Mazzone M, Basilico C, Cavassa S, et al. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest. 2004; 114. 1418-32.
53. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 2005;7:436-51
54. Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004;6:61-73
55. Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 2004;6:75-84 (Pubitemid 38903163)
56. Bardelli A, Maina F, Gout I, et al. Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains. Onocegene 1992;7:1973-8
57. Burgess TL, Sun J, Meyer S, et al. Biochemical characterization of AMG 102:a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther 2010;9:400-9
58. Kim KJ, Wang L, Su YC, et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006;12:1292-8
59. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006;66:1721-9
60. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007;13:6735-42
61. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:6144-52
62. Petrelli A, Circosta P, Granziero L, et al. Abinduced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci USA 2006;103:5090-5
63. Vigna E, Pacchiana G, Mazzone M, et al. "Active" cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res 2008;68:9176-83
64. Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment by a dual function decoy MET-receptor. Cancer Cell 2004;6:61-73
65. Patnaik A, Weiss GJ, Papadopoulos K, et al. Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors. 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2010;28(15 Suppl):2525
66. Morotti A, Mila S, Accornero P, et al. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002;21:4885-93
67. Sattler M, Pride YB, Ma P, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003;63:5462-9
68. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-55
69. Berthou S, Aebersold DM, Schmidt LS, et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004;23:5387-93
70. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-41
71. Eder JP, Heath E, Appleman L, et al. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18S):3526
72. Raeppel S, Claridge S, Saavedra O, et al. N-(3-fluoro-4-(2-arylthieno[3, 2-b] pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2009;19:1323-8
73. Garcia AA, Rosen L, Cunningham CC, et al. Phase 1 study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose [abstract]. J Clin Oncol 2007;18S:3525
74. Laux I, Goldman J, Just R, et al. Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib [abstract 3549]. ASCO 2009
75. Schiller H, Akerley WL, Brugger W, et al. Results from ARQ 197-209: a global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 2010 ASCO Annual Meeting. J Clin Oncol 2010;28(18S):abstract LBA7502
76. Perera T, Lavrijssen T, Jans B, et al. JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models [abstrcat 4837]. AACR meeting 2009
77. Buchanan SG, Hendle J, Lee PS, et al. SGX SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther 2009;8:3181-90
78. Guessous F, Zhang Y, diPierro C, et al. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med Chem 2010;10:28-35
79. Arena S, Benvenuti S, Bardelli A. Genetic analysis of kinome and phosphatome in cancer. Cell Mol Life Sci 2005;62:2092-9
80. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10(8):789-99
81. Bardelli A, Parson DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003;300(5621):949
82. Dorr PT, Fritz WL. Cancer chemotherapy handbook. Elsevier, New York; 1980
83. Maur M, Sessa C. Review: new insights in early clinical studies. Hematol Oncol 2007;25:53-7
84. Zhang J, Jang PL, Gary NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39
85. Lynch TJ, Bell DW, Sordella R, et al. Activating mutation in epidermal growth factor recepors underlying responsivness ofnon-small-cell lung cancer to geftinib. NEJM 2004;350:2129-39
86. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81
87. Weinstein IB. Cancer-addiction to oncogenes: the Achilles heal of cancer. Science 2002;297:63-4
88. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67
89. Ivan M, Bond JA, Prat M, et al. Activated ras and ret oncogenes induce overexpression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 1997;14(20):2417-23
90. Ronsin C, Muscatelli F, Mattei MG, Breathnach R A novel putative receptor protein tyrosine kinase of the met family. Oncogene 1993;8:1195-202
91. Follenzi A, Bakovic S, Gual P, et al. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 2000;19:3041-9
92. Fisher OM, Giordano S, Comoglio PM, et al. Reactive oxygen species mediate MET-receptor transactivation by G-protein-coupled receptors and epidermla growth factor receptor in human carcinoma cells. J Biol Chem 2004;279:28970-8
93. Khoury H, Naujokas MA, Zuo D, et al. HGF converts ErbB2/neu epithelial morphogenesis to cell invasion. Mol Biol Cell 2005;16:550-61
94. Karamouzis MV, Kostantinopoulos PA, Papavassiliuo AG. Trastuzumab-mechanism of action and use. N Engl J Med 2007;357:1664
95. Bardelli A, Basile ML, Audero E, et al. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. Oncogene 1999;18:1139-46
96. Abounader R, Reznik T, Colantuoni C, et al. Regulation of c-Met dependent gene expression by PTEN. Oncogene 2004;23:9173-82
97. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-90
98. Tang Z, Du R, Jiang S, et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 2008;99:911-22
99. Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667-74